2025-10-01 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided. I've included key figures, analysis, and relevant news items.

**Executive Summary:**

Johnson & Johnson (JNJ) is a global healthcare giant focused on pharmaceuticals, medical devices, and consumer health products. While the stock has underperformed the S&P 500 recently, it shows signs of short term surge potential. Analyst consensus leans toward a "Buy" rating, and recent news includes both positive developments (FDA approval) and challenges (acid reflux treatment withdrawal).

---

**1. Performance Relative to S&P 500 (VOO):**

*   **Cumulative Return (JNJ):** 40.98%
*   **Cumulative Return (VOO):** 97.56%
*   **Disparity:** -56.58%
*   **Range of Disparity:** Max: 29.1, Min: -42.8, Current: -29.8
*   **Relative Disparity:** 18.1

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period reflected in the cumulative returns. The current disparity is -29.8, and the relative disparity of 18.1 indicates that the current performance is near the lower end of its historical range relative to the S&P 500.

**Alpha/Beta Analysis (Provided in Table Format):**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.6 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.9 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 351.4 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 379.1 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 412.1 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 425.6 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 377.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 348.4 |
| 2023-2025  | 12.0% | 79.6% | -50.0% | 0.1 | 440.0 |

**Analysis:**

*   **Alpha:** JNJ has struggled to generate positive alpha in most periods, indicating underperformance relative to its risk-adjusted benchmark.  The recent periods (2021-2025) show particularly negative alpha.
*   **Beta:** The beta values are generally low (around 0.1 to 0.5), suggesting that JNJ's price is less sensitive to overall market movements than the S&P 500.
*   **CAGR:** The Compounded Annual Growth Rate (CAGR) has varied significantly. More recent periods (2021-2024) have seen negative growth.
*   **MDD:** The Maximum Drawdown (MDD) has been consistently high, indicating significant potential losses during the observed periods.

**2. Recent Stock Price Movement:**

*   **Current Price:** 182.64
*   **Last Market Data:** {'price': 182.65, 'previousClose': 181.62, 'change': 0.57}
*   **5-day Moving Average:** 178.64
*   **20-day Moving Average:** 177.42
*   **60-day Moving Average:** 171.86

**Analysis:**  The current price is above all moving averages, suggesting a short-term upward trend. The positive change in the last market indicates a continued upward momentum. This sudden change may reflect recent news or events.

**3. Market Risk Indicators and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 62.83
*   **PPO:** 0.0984
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (688 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-09-29)
*   **Recent (20-day) Relative Disparity Change:** 2.0 (+) indicating short-term increase in relative performance.
*   **Expected Return (%):** -37.7 (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** A high MRI (0.9) suggests the investment is considered relatively safe from a broad market perspective, given the current market conditions.
*   **RSI:** An RSI of 62.83 indicates that the stock is approaching overbought conditions, but is not there yet.
*   **PPO:** A positive PPO (0.0984) confirms the upward trend.
*   **Hybrid Signal:**  The signal advocates for a full investment, further reinforced by the "Very Safe" designation and MRI value.
*   **Expected Return:**  The significantly negative expected return (-37.7%) suggests that, even with a recommended "Buy" signal, long-term outperformance versus the S&P 500 is not anticipated.

**4. Recent News & Significant Events (Yahoo Finance):**

*   **[2025-09-30] Prudential Financial Elects Joseph Wolk to Board of Directors:** (Business Wire) - *Indirectly Relevant:* Could indicate future collaborations or strategic shifts.
*   **[2025-09-30] Secure by Design, Not by Chance: Sicura Introduces a New Category of Cyber Defense at InfoSec World 2025:** (PR Newswire) - *Irrelevant*
*   **[2025-09-30] J&J gets FDA approval for Tremfya in paediatric psoriasis:** (Pharmaceutical Technology) - *Positive:*  Expands the market for a key drug.
*   **[2025-09-30] enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer:** (Business Wire) - *Irrelevant*
*   **[2025-09-30] Johnson & Johnson (JNJ) to Withdraw Acid Reflux Treatment in Some Markets:** (Insider Monkey) - *Negative:* Could impact revenue, though the scope is limited to "some markets."
*   **[2025-09-29] Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus:** (Investor's Business Daily) - *Indirectly Relevant:* Indicates potential M&A activity in the pharmaceutical sector, which could influence JNJ.

**Analysis:** The news is a mix of positive and negative. The FDA approval for Tremfya is a clear win. However, the withdrawal of the acid reflux treatment is a negative development.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean = 2.17)
*   **Target Price:** Average = 179.64, High = 206.00, Low = 155.00
*   **Recent Rating Changes:** No changes provided.

**Analysis:**  Analysts generally have a positive outlook on JNJ, with a consensus rating of "Buy." The average target price is slightly below the current price, while the high target price suggests significant upside potential. The lack of recent rating changes makes it difficult to assess the strength of this sentiment.

**5. Recent Earnings Analysis:**

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-07-24   | 2.3  | 23.74 B$   |
| 2025-04-23   | 4.57 | 21.89 B$   |
| 2024-10-23   | 1.12 | 22.47 B$   |
| 2024-07-25   | 1.95 | 22.45 B$   |
| 2025-07-24   | 1.95 | 22.45 B$   |

**Analysis:** The earnings data shows some variability in EPS and revenue. The EPS for 2025-04-23 (4.57) stands out as particularly high. The revenue appears relatively stable.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE    |
|--------------|-------------|--------|
| 2025-06-30   | $78.47B     | 7.06%  |
| 2025-03-31   | $78.11B     | 14.08% |
| 2024-12-31   | $71.49B     | 4.80%  |
| 2024-09-30   | $70.16B     | 3.84%  |
| 2024-06-30   | $71.54B     | 6.55%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue shows a moderate increase over the period. Profit margins are consistently high, indicating strong pricing power.
*   **Capital and Profitability:** Equity has increased over the period. ROE has fluctuated, with a high in 2025-03-31.

**7. Comprehensive Analysis (Summary):**

*   **Underperformance:** JNJ has underperformed the S&P 500 significantly.
*   **Short-Term Surge:** Recent price action suggests a short-term surge is happening.
*   **Mixed News:** The news flow is mixed (FDA approval vs. product withdrawal).
*   **Analyst Sentiment:** Analysts maintain a "Buy" rating, but target prices are varied.
*   **Solid Financials:** JNJ has a solid financial position with high profit margins.
*   **High MRI:** The MRI indicator is high, suggesting a safe investment profile.
*   **Negative expected Return:** However, expected future return is negative.

**Overall, JNJ appears to be a relatively safe investment with potential for short-term gains, but it has underperformed the broader market and is not expected to outperform in the long term. The recent price increase and high MRI suggest some safety, but the negative expected return and withdrawal of acid reflux treatment are cause for concern.**
